Alder BioPharmaceuticals Inc. uniquely identifies, develops and manufactures novel antibody therapeutics to alleviate human suffering in cancer, pain, cardiovascular and autoimmune and inflammatory disease areas. The company's investigational monoclonal antibody for migraine, ALD403, inhibits a well-validated molecule shown to trigger migraine attacks, calcitonin gene-related peptide (CGRP), and will enter this clinic this quarter.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/19/12 | $38,000,000 | Series D |
Delphi Ventures H.I.G. Ventures Novo Ventures Sevin Rosen Funds TPG Biotech Ventures West WRF Capital | undisclosed |
